Bayer has terminated a Phase II trial evaluating riociguat in patients with pulmonary hypertension due to fears raised by an …

Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

